The government of Nepal has permitted to import, sales and distribution of Remdesivir, an anti-viral drug used in the treatment of COVID-19.
According to Dr. Samir Kumar Adhikari, Deputy Spokesperson at the Ministry of Health and Population, the Department of Drug Administration has issued permission to two Nepali companies whereas one is from India.
In the context of no antidote against COVID-19 developed as of now, the Remdesivir is used in Nepal for the research purpose.
The WHO has said says the world’s largest randomized trial of COVID-19 treatments found “conclusive evidence” that remdesivir, a drug used to treat U.S. President Donald Trump when he fell ill, has little or no effect on severe cases.
The drugs might have an effect on the coronavirus, said the WHO and added that the study, which was not peer-reviewed, found that four treatments tested – remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon- had “ little or no effect” on whether or not patients died within about a month or whether hospitalized patients recovered.
European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients.
WHO said the study, which covered more than 30 countries, looked at the effects of the treatments on overall death rates, whether or not patients need breathing machines, and how much time patients spent recovering in hospitals.
Meanwhile, Pharmaceutical giant Pfizer says it hopes to seek authorization for its COVID-19 vaccine in mid-November.
“So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the US soon after the safety milestone is achieved in the third week of November,” said CEO Albert Bourla in a statement.
The US Company, which is developing the vaccine alongside Germany’s BioNTech SE, has previously said it would know by the end of this month whether its product was effective.
The Oxford vaccine, meanwhile, is not expected to confirm whether it is effective until the end of the year.